Savior Lifetec (4167) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.026x

Based on the latest financial reports, Savior Lifetec (4167) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-98.65 Million ≈ $-3.11 Million USD) by net assets (NT$3.78 Billion ≈ $119.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Savior Lifetec - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Savior Lifetec's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Savior Lifetec for a breakdown of total debt and financial obligations.

Savior Lifetec Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Savior Lifetec ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
New Power Plasma Co.Ltd
KQ:144960
0.051x
Lucky Cement Co
TW:1108
0.039x
Midnight Sun Mining Corp
V:MMA
-0.101x
BayWa AG vNa
XETRA:BYW6
0.166x
Barings Participation Investors (the Trust)
NYSE:MPV
0.033x
Bossa Ticaret ve Sanayi Isletmeleri TAS
IS:BOSSA
0.021x
Dynamix Corporation Class A Ordinary Shares
NASDAQ:DYNX
-0.005x
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
-0.162x

Annual Cash Flow Conversion Efficiency for Savior Lifetec (2011–2025)

The table below shows the annual cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 4167 company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 NT$3.78 Billion
≈ $119.12 Million
NT$-21.04 Million
≈ $-662.91K
-0.006x -103.77%
2024-12-31 NT$3.52 Billion
≈ $110.78 Million
NT$518.38 Million
≈ $16.33 Million
0.147x +27.87%
2023-12-31 NT$3.36 Billion
≈ $106.01 Million
NT$387.95 Million
≈ $12.22 Million
0.115x -33.27%
2022-12-31 NT$3.37 Billion
≈ $106.08 Million
NT$581.77 Million
≈ $18.33 Million
0.173x +440.04%
2021-12-31 NT$3.31 Billion
≈ $104.37 Million
NT$-168.34 Million
≈ $-5.30 Million
-0.051x -285.45%
2020-12-31 NT$3.33 Billion
≈ $104.92 Million
NT$91.25 Million
≈ $2.87 Million
0.027x -61.21%
2019-12-31 NT$2.21 Billion
≈ $69.75 Million
NT$156.40 Million
≈ $4.93 Million
0.071x +169.06%
2018-12-31 NT$1.86 Billion
≈ $58.47 Million
NT$-189.84 Million
≈ $-5.98 Million
-0.102x -184.82%
2017-12-31 NT$2.16 Billion
≈ $68.15 Million
NT$260.89 Million
≈ $8.22 Million
0.121x +435.93%
2016-12-31 NT$2.12 Billion
≈ $66.77 Million
NT$-76.09 Million
≈ $-2.40 Million
-0.036x +86.25%
2015-12-31 NT$1.59 Billion
≈ $50.15 Million
NT$-415.82 Million
≈ $-13.10 Million
-0.261x -265.61%
2014-12-31 NT$1.29 Billion
≈ $40.75 Million
NT$-92.41 Million
≈ $-2.91 Million
-0.071x -16.66%
2013-12-31 NT$1.39 Billion
≈ $43.93 Million
NT$-85.39 Million
≈ $-2.69 Million
-0.061x +65.70%
2012-12-31 NT$1.27 Billion
≈ $40.16 Million
NT$-227.59 Million
≈ $-7.17 Million
-0.179x +48.89%
2011-12-31 NT$1.31 Billion
≈ $41.38 Million
NT$-458.82 Million
≈ $-14.46 Million
-0.349x --

About Savior Lifetec

TWO:4167 Taiwan Biotechnology
Market Cap
$185.34 Million
NT$5.88 Billion TWD
Market Cap Rank
#16823 Global
#831 in Taiwan
Share Price
NT$18.95
Change (1 day)
-0.79%
52-Week Range
NT$17.00 - NT$22.00
All Time High
NT$40.63
About

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more